Evidence map›Paper›PMID 42851449›Full record

ArticleClinical kidney journal2026

Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation.

Valentin Maisons, Margaux Costes-Albrespic, Sophie Liabeuf, Solène M Laville, Ziad Massy, Angelo Karaboyas, Roberto Pecoits-Filho, Emilie Moutard, Marie Metzger, Jean-Michel Halimi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valentin MaisonsUniversité de Tours, CHU de Tours, Service de Néphrologie, Hôpital Bretonneau, Tours, France.ORCID https://orcid.org/0000-0002-0376-7894
Margaux Costes-AlbrespicCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID https://orcid.org/0009-0004-7910-698X
Sophie LiabeufPharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France.ORCID https://orcid.org/0000-0001-5384-9006
Solène M LavillePharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France.
Ziad MassyCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID https://orcid.org/0000-0001-5771-5996
Angelo KaraboyasArbor Research Collaborative for Health, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0001-8846-5360
Roberto Pecoits-FilhoArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Emilie MoutardCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.
Marie MetzgerCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.
Jean-Michel HalimiUniversité de Tours, CHU de Tours, Service de Néphrologie, Hôpital Bretonneau, Tours, France.
Etienne DantanINSERM U1246 - SPHERE (methodS in Patient-centered outcomes and HEalth ResEarch), Université de Tours, Nantes Université, Tours, Nantes, France.ORCID https://orcid.org/0000-0001-7137-5051
Natalia Alencar de PinhoCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID https://orcid.org/0000-0002-0438-6487
Bénédicte SautenetUniversité de Tours, CHU de Tours, Service de Néphrologie, Hôpital Bretonneau, Tours, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renin-angiotensin system (RAS) inhibitors are a cornerstone of cardiovascular and kidney risk modification in chronic kidney disease (CKD). Yet, they are often discontinued in advanced CKD to limit adverse effects or to delay kidney replacement therapy (KRT). Methods: From the CKD-Renal Epidemiology and Information Network prospective cohort study, we selected participants with an estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m Results: Among the 1434 patients included (median age 68 years, median eGFR 25 ml/min/1.73 m Discussion: RAS inhibitor discontinuation was strongly associated with MACE and KRT risks, major causes of morbidity, and mortality in advanced CKD. Our findings, consistent with prior data, suggest the risk-benefit balance favors continued use with close monitoring.

Indexed as

epidemiologyrenin–angiotensin system inhibitorstarget-trial emulation

Identifiers

PMID42851449
PMCPMC13645658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.